10 results
10-K
2020 FY
NEXI
Neximmune Inc
31 Mar 21
Annual report
4:02pm
focused on the treatment of chronic renal disease. Prior to that, he served as Chief Executive Officer of RegenMed Therapeutics. He served as Chief
424B4
NEXI
Neximmune Inc
16 Feb 21
Prospectus supplement with pricing info
4:38pm
Officer and as a member of the board of directors of inRegen, a clinical-stage cellular therapeutics company focused on the treatment of chronic renal
S-1/A
1a5wn
8 Feb 21
IPO registration (amended)
7:29am
S-1
9ozup3v8
19 Jan 21
IPO registration
4:38pm
DRS/A
eg68oszv2i1qahpxa5
15 Jan 21
Draft registration statement (amended)
12:00am
DRS
cfai38amylvvn0n8hjf5
14 Dec 20
Draft registration statement
12:00am
- Prev
- 1
- Next